双鹭药业(002038) - 2015 Q1 - 季度财报

Financial Performance - Operating revenue for the first quarter was CNY 277,303,455.96, a decrease of 3.84% compared to the same period last year[4] - Net profit attributable to shareholders was CNY 179,088,812.64, an increase of 6.08% year-on-year[4] - Basic earnings per share rose by 5.41% to CNY 0.39[4] - Net cash flow from operating activities increased by 73.65% to CNY 166,821,451.54 compared to the previous year[4] - Investment income increased by 111.25% year-on-year, mainly due to gains from the disposal of long-term equity investments[13] - The estimated net profit attributable to shareholders for the first half of 2015 is expected to range from CNY 35,726.92 million to CNY 46,445 million, representing a change of 0.00% to 30.00%[15] Assets and Shareholder Information - Total assets at the end of the reporting period were CNY 3,513,062,323.23, reflecting a growth of 5.84% from the end of the previous year[4] - Net assets attributable to shareholders increased by 6.23% to CNY 3,344,158,231.69[4] - The total number of common shareholders at the end of the reporting period was 23,708[8] - The largest shareholder, Xu Mingbo, held 22.54% of the shares, amounting to 102,974,003 shares[8] - The company did not engage in any repurchase transactions among the top ten shareholders during the reporting period[9] Changes in Financial Position - Prepaid accounts increased by 86.93% compared to the beginning of the reporting period, attributed to higher prepayments for raw materials and testing fees[13] - Other receivables decreased by 98.14% compared to the beginning of the reporting period, due to the repayment from Zhongke Biological Pharmaceutical Co., Ltd.[13] - Deferred income tax liabilities increased by 66.55% compared to the beginning of the reporting period, resulting from changes in the fair value of available-for-sale financial assets[13] - Financial expenses decreased by 90.77% year-on-year, mainly due to increased deposits and interest income[13] Other Income and Gains - The company reported non-recurring gains and losses totaling CNY 14,839,478.99 for the period[6] - Fair value changes in financial assets led to a 745.86% increase in fair value change income year-on-year[13] - Other comprehensive income increased by 106.65% compared to the beginning of the reporting period, due to changes in the fair value of available-for-sale financial assets[13] Corporate Governance - The chairman of Beijing Shuanglu Pharmaceutical Co., Ltd. is Xu Mingbo[20] - The earnings conference call took place on April 28, 2015[20]